Sentences with phrase «in preclinical models for»

Monitoring Healing Progression and Characterizing the Mechanical Environment in Preclinical Models for Bone Tissue Engineering.

«Stem cell - based therapy for targeting skin - to - brain cancer: Stem cells loaded with oncolytic viruses show promising results in preclinical models for targeting skin cancer metastases in the brain.»

Combining their strategy with an existing immunotherapy treatment that works by releasing the «brakes» on immune cells, they found they could shrink melanoma tumors, and prolong survival in preclinical models for melanoma.

Not exact matches

Research in recent years has covered both preclinical basic research and the transfer of the results generated from studies of mouse models to clinically applicable techniques for treating female infertility.

The other study — Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma — published March 30, shows how drugs targeting PI3K and MAPK could represent promising candidates for glioblastoma therapy.

In a study of preclinical models of colorectal cancer, the researchers identified an underlying mechanism for the activation of p53 by FL118.

«The model for preclinical studies to predict with great accuracy which drugs would work in the clinic was developed a decade ago,» says Dr. Chesi.

Long - awaited breakthroughs in developing preclinical animal models are signaling a new era for liver - targeted viruses and beyond

Overall, this work illustrates that better understanding the basic biology of the immune system in preclinical models may open up a window for the development of novel treatments for human autoimmune disease.

«Novel imaging model helps reveal new therapeutic target for pancreatic cancer: Antisense treatment in preclinical models shows effectiveness against deadly tumors.»

«This study for the first time shows increased expression of IL - 33 in AMD and further demonstrates a role for glia - derived IL - 33 in the accumulation of myeloid cells in the outer retina, loss of photoreceptors, and functional impairment of the retina in preclinical models of retina stress,» the authors note.

Our finding of similarity in clinical progression between human patients and Huntington's disease monkeys suggests monkeys could become a preclinical, large animal model for the development of new treatments.»

Katherine W. Klinger, PhD, Senior Vice President for Genetics and Genomics at the Genzyme Corporation, and Assistant Clinical Professor in the Department of Pediatrics at the University of Connecticut School of Medicine suggested that for an orphan disease it may be necessary to use multiple animal models in the preclinical research stage, because one animal model may not fully recapitulate the human disease.

W. Bogers: PhD in immunology and 20 years of experience with NHP models for the preclinical evaluation of HIV vaccine candidates as well as testing antivirals.

«The preclinical results in our animal models are really exciting and have provided the momentum for me to continue on this project, even after Novartis indicated that it no longer wished to maintain this collaboration.»

Together, this translational program is developed within the National Cancer and Cognition Platform (CNO / Ligue Nationale contre le cancer), with the aim to collaborate in a structured way with French oncology groups, research teams as well as pharmaceutical industry, by providing preclinical models and guidance on standard operating procedures for ancillary or future studies in identified population at risk.

EOS100850 is currently being evaluated for safety and efficacy in preclinical models.

In order to efficiently evaluate the newly designed vaccine candidates before testing them in clinical trials there is a need for development of reliable preclinical modelIn order to efficiently evaluate the newly designed vaccine candidates before testing them in clinical trials there is a need for development of reliable preclinical modelin clinical trials there is a need for development of reliable preclinical models.

This model offers unique capabilities for preclinical assessment of thrombosis risk in a patient - specific manner, including efficacy testing of anti-thrombotic agents, elucidation of mechanism of action, and, potentially, biomarker identification, all providing a much - needed platform for drug discovery and development.

The comprehensive information presented for each cell therapy includes: an overview of the therapy, a list of therapeutic cells utilized in the specific treatment, mode and regimen of cell delivery, mechanism of action, formulation, in vitro data, animal models, preclinical data and related clinical trials.

Both recent experience with immunotherapy for clearance of Aβ in AD, and their own (and Prothena's) experience with AS - clearing immunotherapies in animal models, indicate that in order to be effective as disease - modifying agents when administered alone, therapies that remove proteinaceous aggregates from the brain must be initiated in the early clinical or even preclinical stages of the disease, before the burden of other forms of aging damage becomes entrenched.

«Nutrient scavenging by autophagy is a process that tumors hijack to meet their energetic requirements and to provide the necessary cellular building blocks for growth in a stressed tumor micro-environment» said White, «Preclinical models have demonstrated a critical role for autophagy in multiple cancer types.»

It is currently being evaluated for safety and efficacy in preclinical models with a Phase I trial expected to begin in 2019.

The phenotyping platforms of PHENOMIN - ICS area, adapted to study genetically modified mouse models, can also be used for preclinical studies, including the validation of therapeutic targets, as well as pharmaceutical and toxicological studies in mice.

AFF 1: Preclinical Efficacy Data AFF 1 was then tested for preclinical efficacy in two models of human synucleinopathy: mThy1 - AS mice, and also PDGF - AS mice expressing WT human AS under the PDGF - β promoter — a model with closer neuropathological and metabolic resemblance to LPreclinical Efficacy Data AFF 1 was then tested for preclinical efficacy in two models of human synucleinopathy: mThy1 - AS mice, and also PDGF - AS mice expressing WT human AS under the PDGF - β promoter — a model with closer neuropathological and metabolic resemblance to Lpreclinical efficacy in two models of human synucleinopathy: mThy1 - AS mice, and also PDGF - AS mice expressing WT human AS under the PDGF - β promoter — a model with closer neuropathological and metabolic resemblance to LBD than PD.

We have recently identified which cells are uniquely responsible for the metastasis formation in OSCC, and they exhibit the following characteristics: i) they are exclusive in their ability to generate metastases; ii) they express the fatty acid translocase CD36, and express a unique lipid metabolic signature; iii) they directly link metastasis predisposition to dietary fat content; iv) they increase their metastatic initiation potency when treated with palmitic acid; v) they are highly sensitive to CD36 inhibition, which almost completely abolishes their metastatic potential in preclinical models (Pascual et al., Nature 2016).

With our anti-TIGIT antibody program, we saw anti-tumor efficacy and reactivation of T - cells in preclinical models which is encouraging for the potential of this product as a monotherapy

Previously we reported the development of liposome - based vaccines and their efficacy and safety in preclinical mouse models for tauopathy.

Such models will allow for further understanding of critical genes and microRNAs involved in sarcoma development, progression and metastasis and can be utilized as preclinical models for therapeutic testing and efficacy.

Then, in preclinical models of MYCN leukemia, the researchers tested a strategy of knocking out the gene for the safety - valve protein.

and affinity of antibody ACI - 5400 were characterized by a panel of methods: (i) measuring the selectivity for a specific phospho - Tau epitope known to be associated with tauopathy, (ii) performing a combination of peptide and protein binding assays, (iii) staining of brain sections from mouse preclinical tauopathy models and from human subjects representing six different tauopathies, and (iv) evaluating the selective binding to pathological epitopes on extracts from tauopathy brains in non-denaturing sandwich assays.

The diverse group of experts has developed a biorepository of patient - derived tissues, which will be used for testing investigational drugs in preclinical models.

Now, three papers published concurrently in Science have shown CRISPR can treat a genetic disease in a postnatal mouse model, an important proof of concept for future preclinical and clinical work.

Such models will allow for further understanding of critical genes and microRNAs involved in sarcoma development, progression and metastasis and utilized as preclinical models for therapeutic testing and efficacy.

His research group actively collaborates with several pharmaceutical companies to provide valuable preclinical data in animal models for their targeted drugs.

The endocannabinoid system regulates energy homeostasis through G protein — coupled cannabinoid - 1 receptors5, 6 located in the central nervous system and in various peripheral tissues, including adipose tissue, muscle, the gastrointestinal tract, and the liver.7 While peripheral cannabinoid - 1 receptor activation decreases adiponectin production in adipocytes, 8 central cannabinoid - 1 receptor activation in preclinical studies stimulates eating, decreases muscle, and stimulates hepatic and adipose tissue lipogenic pathways in animal models of obesity.9 In genetic and diet - induced obesity, rimonabant, a selective cannabinoid - 1 receptor blocker, reduces overactivation of the central8, 10 and peripheral11, 12 endocannabinoid system8, 10,13 and prevents weight gain and associated metabolic disorders, thus revealing a novel strategy for the treatment of obesity and related cardiometabolic disorderin the central nervous system and in various peripheral tissues, including adipose tissue, muscle, the gastrointestinal tract, and the liver.7 While peripheral cannabinoid - 1 receptor activation decreases adiponectin production in adipocytes, 8 central cannabinoid - 1 receptor activation in preclinical studies stimulates eating, decreases muscle, and stimulates hepatic and adipose tissue lipogenic pathways in animal models of obesity.9 In genetic and diet - induced obesity, rimonabant, a selective cannabinoid - 1 receptor blocker, reduces overactivation of the central8, 10 and peripheral11, 12 endocannabinoid system8, 10,13 and prevents weight gain and associated metabolic disorders, thus revealing a novel strategy for the treatment of obesity and related cardiometabolic disorderin various peripheral tissues, including adipose tissue, muscle, the gastrointestinal tract, and the liver.7 While peripheral cannabinoid - 1 receptor activation decreases adiponectin production in adipocytes, 8 central cannabinoid - 1 receptor activation in preclinical studies stimulates eating, decreases muscle, and stimulates hepatic and adipose tissue lipogenic pathways in animal models of obesity.9 In genetic and diet - induced obesity, rimonabant, a selective cannabinoid - 1 receptor blocker, reduces overactivation of the central8, 10 and peripheral11, 12 endocannabinoid system8, 10,13 and prevents weight gain and associated metabolic disorders, thus revealing a novel strategy for the treatment of obesity and related cardiometabolic disorderin adipocytes, 8 central cannabinoid - 1 receptor activation in preclinical studies stimulates eating, decreases muscle, and stimulates hepatic and adipose tissue lipogenic pathways in animal models of obesity.9 In genetic and diet - induced obesity, rimonabant, a selective cannabinoid - 1 receptor blocker, reduces overactivation of the central8, 10 and peripheral11, 12 endocannabinoid system8, 10,13 and prevents weight gain and associated metabolic disorders, thus revealing a novel strategy for the treatment of obesity and related cardiometabolic disorderin preclinical studies stimulates eating, decreases muscle, and stimulates hepatic and adipose tissue lipogenic pathways in animal models of obesity.9 In genetic and diet - induced obesity, rimonabant, a selective cannabinoid - 1 receptor blocker, reduces overactivation of the central8, 10 and peripheral11, 12 endocannabinoid system8, 10,13 and prevents weight gain and associated metabolic disorders, thus revealing a novel strategy for the treatment of obesity and related cardiometabolic disorderin animal models of obesity.9 In genetic and diet - induced obesity, rimonabant, a selective cannabinoid - 1 receptor blocker, reduces overactivation of the central8, 10 and peripheral11, 12 endocannabinoid system8, 10,13 and prevents weight gain and associated metabolic disorders, thus revealing a novel strategy for the treatment of obesity and related cardiometabolic disorderIn genetic and diet - induced obesity, rimonabant, a selective cannabinoid - 1 receptor blocker, reduces overactivation of the central8, 10 and peripheral11, 12 endocannabinoid system8, 10,13 and prevents weight gain and associated metabolic disorders, thus revealing a novel strategy for the treatment of obesity and related cardiometabolic disorders.

Over 170 carefully curated, well - characterized patient - derived xenograft tumor models are available for use in your facility, or use Horizon's comprehensive preclinical in vivo efficacy service.

Tags for this Online Resume: Business Development, CRO Services, Biologics, Small Molecules, Preclinical Drug Development, Drug Discovery, In Vivo efficacy models, Preclinical R&D, ELISA, Cardiovascular, Cellular, Injections, Oncology, Research, Pharmaceutical, Business Development Manager, Cancer, Applications, Automation, Field Applications Scientist, Cell based assays